Shortly thereafter, the same group found that melanocyte-originated lesions ranging from a benign nevus, dysplastic nevi, and melanoma all express functional TSHR, with an upregulated expression in premalignant and malignant lesions, implying a higher sensitivity to TSH [48]. This evidence concerns the gene TSHR and melanoma.